Context: Some patients with primary hyperparathyroidism (PHPT) develop renal calcifications. Investigation of urinary and nonurinary risk factors are essential.
prevalence of nephrolithiasis in PHPT with prevalence ranging from 5% to 60% (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . However, only two studies have clearly distinguished between nephrolithiasis and nephrocalcinosis in PHPT, reporting a prevalence of nephrocalcinosis of 1% and 10% (17, 18) . The etiology behind renal calcifications is multifactorial but hypercalciuria is considered an important factor (12) . Some, but not all, studies have observed a higher renal calcium excretion in PHPT with nephrolithiasis compared with patients without nephrolithiasis (3, 5, 11, 12) . Other indices associated with renal calcifications in PHPT are young age and male sex, whereas the degree of hypercalcemia, serum levels of PTH, and 1,25-dihydroxyvitamin-D [1, 25(OH) 2 D] have shown conflicting results (5, 9, 11-13, 16, 17, 19) . Because only a subgroup of patients with PHPT develop renal calcifications, it could be advantageous to identify urinary and nonurinary risk factors and including potential biochemical differences between patients (1) with or without renal calcifications, (2) with or without nephrolithiasis, and (3) with or without nephrocalcinosis. Moreover, at the Fourth International Workshop regarding PHPT, it was suggested that renal calcifications may be underestimated with current renal imaging. A request was forwarded for more data on improved methods determining renal calcifications and associations between renal stone formation and biochemistry (21) .
Therefore, we aimed to determine the prevalence of renal calcifications (nephrolithiasis and nephrocalcinosis) from routine CT scans of the kidneys and urinary tract in a Danish cohort of patients with PHPT. Furthermore, using a nested case-control design, we aimed to assess potential risk factors associated with renal calcifications as well as to elucidate potential biochemical differences between patients with nephrolithiasis and nephrocalcinosis.
Materials and Methods
We identified all patients diagnosed with PHPT at Aarhus University Hospital from 2005 to 2015 through the Danish National Patient Register. We retrieved biochemical data from the Department of Clinical Biochemistry, Aarhus University Hospital, to validate the diagnosis for each patient. We only included patients with ionized calcium levels above the upper limit of reference range and PTH levels (both defined by the mean of two measurements) in the upper third or above the upper limit of the reference range. Patients diagnosed with chronic kidney diseases (CKDs; including renal transplant) prior to the PHPT diagnosis were excluded, as CKD is associated with tertiary hyperparathyroidism. Moreover, we excluded patients with multiple endocrine neoplasia and parathyroid cancer. Based on calcium-to-creatinine clearance ratio .0.02, familial hypocalciuric hypercalcemia (FHH) was excluded (22) . If the calcium-to-creatinine clearance ratio was ,0.02, a genetic test was performed to exclude FHH type 1 (inactivating mutations in the calcium-sensing receptor).
Ionized calcium and PTH measurements closest to the day of diagnosis were selected for each patient. Additionally, we obtained data on plasma levels of total calcium, creatinine, phosphate, 24-hour renal calcium excretion, 25-hydroxyvitamin D (25-OHD), and 1,25(OH) 2 D. The estimated glomerular filtration rate (eGFR) was calculated based on age, sex, and creatinine (23) . In accordance with the criteria defined by the National Kidney Foundation, eGFR was converted into stages of CKDs (24) . The calcium-phosphate product (CaPproduct) was calculated by multiplying total calcium by serum phosphate levels on samples taken simultaneously (reference ,4.4 mmol 2 /L 2 ). In females and males, hypercalciuria was defined as a renal calcium excretion .7 mmol/24 hours or .9 mmol/24 hours, respectively.
During the time of study, a CT scan of the kidneys and urinary tract was recommended at our department as part of the routine diagnostic workup of patients with newly diagnosed PHPT at our department. All CT findings were reviewed by two investigators (H.E.-S. and L.S.B.) and were divided into nephrocalcinosis (calcifications of the renal parenchyma) or nephrolithiasis in the calyx, pelvis, ureters, and bladder (25) .
Ethics
The Danish Data Protection Agency was notified about the study (no. 1-16-02-135-15) and the Danish Health and Medicines Authority granted access to retrieve data from hospital charts (no. 3-3013-948/1+2).
Biochemistry
Standard laboratory methods for measurements of plasma and urinary calcium, creatinine, and phosphate were used. Plasma intact PTH levels were measured using a secondgeneration electrochemiluminescent immunoassay on an automated instrument (Cobas 6000; Roche Diagnostics). Plasma 25-OHD was analyzed by isotope dilution liquid chromatographytandem mass spectrometry (26 Similar, a multiple linear regression model was used to assess the relationship between eGFR and biochemical indices reporting the correlation coefficient (r) for the overall model, as well as partial correlation coefficients (r p ) for identified independent predictors. We calculated the area under receiver operating characteristics curves to assess the performance of 24-hour urinary calcium as a predictor of nephrolithiasis.
Descriptive statistics are shown as median with interquartile range (IQR; 25% and 75% percentile), unless otherwise stated. P values ,0.05 were considered statistically significant. Data were analyzed with SPSS version 24 (IBM, New York, New York).
Results
We identified 792 patients with PHPT (.99% white) among whom 617 patients (78%) had a CT scan preformed (Fig. 1) . The median age of studied patients was 63 (IQR: 55 to 71) years and 77% were females. Table 1 shows clinical and biochemical characteristics of all included patients, as well as stratification by the presence of renal calcifications.
Prevalence of renal calcifications
A total of 144 (23%) patients had renal calcifications, of which seven (5%) had both nephrolithiasis and nephrocalcinosis. Nephrolithiasis was present in 76 (53%) and nephrocalcinosis in 75 (52%) of these patients. Among the 76 patients with nephrolithiasis, 52 (68%) had unilateral nephrolithiasis and 24 (32%) had bilateral nephrolithiasis. Of the 75 patients with nephrocalcinosis, 49 (65%) had unilateral nephrocalcinosis and 26 (35%) had bilateral nephrocalcinosis.
Characteristics of patients with renal calcifications
Age and sex did not differ between patients with and without renal calcifications (Table 1) . Compared with patients without renal calcifications, patients with calcifications had a slightly but significantly lower body mass index (BMI) as well as significantly higher levels of PTH, Ca 2+ , and 24-hour urinary calcium but lower plasma phosphate levels ( Table 1) . Table 2 compares patients with nephrolithiasis to patients with nephrocalcinosis. Renal calcifications were equally frequent among sexes. Body height, weight, and BMI were significantly lower in patients with nephrocalcinosis compared with patients with nephrolithiasis (P , 0.05). Furthermore, plasma levels of phosphate and the CaP-product were significantly higher in patients with nephrocalcinosis compared with patients with nephrolithiasis. However, none of the patients with nephrocalcinosis had a CaP-product above 4.4 mmol 2 /L 2 .
Among patients with nephrolithiasis, 67% had hypercalciuria. Among patients without nephrolithiasis, 49% had hypercalciuria. Overall, hypercalciuria was significantly more prevalent among patients with nephrolithiasis (P ,0.01). Analyzing 24-hour urinary calcium as a predictor Figure 1 . Flowchart of study participants.
of nephrolithiasis showed a poor diagnostic accuracy with an area under the curve below 0.6 (95% CI: 0.53 to 0.67).
Predictors of renal calcifications
Dividing Ca 2+ levels into tertiles showed a significantly increased prevalence of renal calcifications with increased levels of Ca 2+ (P trend ,0.001). Patients with moderate-to-severe hypercalcemia ($1.47 mmol/L) had a significantly higher prevalence of renal calcifications (33.5%) compared with the prevalence in patients with mild-to-moderate (20.6%, P , 0.01) or only mild (15.9%, P , 0.001) hypercalcemia (Fig. 2) . However, the prevalence did not differ between patients with mild and mild-to-moderate hypercalcemia (P = 0.22). Similarly, dividing PTH levels into tertiles, the prevalence of renal calcifications was 17%, 23%, and 30% in patients with PTH of ,9.0 pmol/L, PTH of 9.0 to 12.8 pmol/L, and PTH of .12.8 pmol/L, respectively (P trend ,0.01).
In logistic regression analyses, risk of any renal calcifications and risk of nephrolithiasis were significantly increased in the highest compared with the lowest tertile of PTH and Ca 2+ levels, whereas risk of nephrocalcinosis only was significantly increased in patients in the highest compared with the lowest tertile of Ca 2+ (Table 3) . However, in adjusted analyses, only high levels of Ca 2+ were significantly associated with risk of any renal calcifications (OR: 1.922; 95% CI: 1.065 to 3.469). In crude analysis, a high 24-hour renal calcium excretion was associated with increased risk of renal calcifications, but the association did not remain statistically significant after mutual adjustments (Table 3) . In crude analyses, plasma phosphate levels as well as the CaP-product were associated with a lower risk of any calcifications and nephrolithiasis among those in the highest compared with the lowest tertile. However, in adjusted analyses, only risk of nephrolithiasis was significantly lower among those with a CaP-product in the highest compared with the lowest tertile. Plasma levels of 1,25(OH) 2 D were not associated with risk of calcifications (data not shown).
Renal function
Based on the calculated eGFR, 44% had a normal renal function (eGFR .90 mL/min), 44% had an eGFR Number of subjects (%) or median with IQR (25% to 75%). a P value comparing patients with and without calcifications.
b n = 561.
c n = 606.
d n = 518.
e n = 539.
f n = 414.
g n = 563.
between 60 and 89 mL/min (CKD stage 2), 11% had an eGFR between 30 and 59 mL/min (CKD stage 3), and 1% had an eGFR below 30 mL/min (CKD stages 4 and 5). The prevalence of renal calcifications varied between 17% and 22% in the different CKD stages and did not differ significantly between CKD stages (P = 0.71). In bivariate correlation analyses, eGFR correlated with plasma 1,25(OH) 2 D and 24-hour urinary calcium, whereas eGFR and PTH correlated inversely (Table 4) . In a multiple regression model (overall model: r = 0.466, P , 0.001), eGFR was significantly associated with 1,25(OH) 2 D (r p = 0.189, P , 0.001) and 24-hour urinary calcium (r p = 0.361, P , 0.001), inversely associated with ionized calcium (r p = -0.155, P , 0.01) and PTH (r p = -0.145, P , 0.01), and borderline significantly associated with plasma phosphate (r p = -0.096, P = 0.06).
Characteristics of patients not examined with CT scans of the kidneys and urinary tract A CT scan of the kidneys and urinary tract was not performed in 175 (22%) of the patients with verified PHPT (Fig. 1) Number of subjects (%) or median with IQR (25%-75%). a n = 51.
b n = 57.
c n = 55. Additionally, there were an overrepresentation of females among patients without CT scans (84% vs 77%, P , 0.05).
Discussion
In patients with PHPT, the overall prevalence of renal calcifications from routine CT scans of the kidneys and urinary tract was 23%. The severity of the disease in regard to grade of hypercalcemia, PTH levels, and 24-hour urinary calcium was associated with renal calcifications. Patients with nephrocalcinosis differed from patients with nephrolithiasis by higher levels of phosphate and a higher CaP-product.
Prevalence of renal calcifications
Several studies have assessed the prevalence of nephrolithiasis in PHPT. However, the prevalence has varied widely, with some studies reporting a very low prevalence from 5% to 10% (6, 14, 16, 19) , most studies reporting a prevalence between 20% and 30% (4, 5, 10, 13, 15, 17, 18), and some studies reporting a prevalence of renal calcifications as high as 40% to 60% (7, 9, 11, 12, 20) . This wide range might be caused by differences in study populations, study design, and methods used to determine renal calcifications. Two of the studies reporting a very low prevalence of nephrolithiasis were retrospective studies based on medical record reviews (6, 16) . This is opposed to Cipriani et al. (20) reporting a prevalence of nephrolithiasis of 55% in 140 patients with moderate disease and Mollerup et al. (7) reporting a prevalence of 50% in 297 patients with moderate to severe disease. In our study, most of the patients had mild disease, supporting the notion that levels of serum calcium and PTH are of importance for risk of renal calcifications. Among patients with renal calcifications, we found a prevalence of nephrocalcinosis of 12%. Nephrocalcinosis is defined as deposition of either calcium oxalate or calcium phosphate in the renal parenchyma and is a wellknown complication to PHPT (27) . Most studies have only focused on nephrolithiasis, whereas only two studies have reported prevalence of nephrocalcinosis in PHPT. In a former study, from our department, investigating 177 patients (subsample of our study population) with PHPT, nephrocalcinosis was reported in 10% (17). Elkoushy et al. (18) reported a prevalence of nephrocalcinosis of 1.2%, which is very low compared with our study. However, asymptomatic patients did not have a CT scan of the kidneys and urinary tract performed, which may underestimate the true prevalence because nephrocalcinosis mostly is an asymptomatic disease.
In our study, all included patients diagnosed with PHPT underwent a routine diagnostic workup with lowdose CT scans. A meta-analysis evaluating the diagnostic performance of low-dose CT as a diagnostic tool for nephrolithiasis reported a pooled sensitivity of 97% and a pooled specificity of 95% (28) . In comparison, the diagnosis of nephrolithiasis with ultrasound has been reported with a pooled sensitivity of 45% and a pooled specificity of 88% (29) . Ultrasound often fails to diagnose ureteral stones (30) . However, Boyce et al. (31) reported ultrasound as superior to CT in the diagnostics of mild to moderate nephrocalcinosis in patients with hypoparathyroidism. A study by Moosgaard et al. (10) , investigating 289 PHPT patients with CT scans of the kidneys and urinary tract, found a prevalence of renal calcifications of 18%. In contrast, the prevalence of nephrolithiasis in studies using ultrasound varies from 7% to 55% (10, 13, 18, 19) . However, it is not clear whether this is caused by imprecision of the method or different inclusion and exclusion criteria used in the different studies. Further studies evaluating different modalities to assess nephrolithiasis and nephrocalcinosis in PHPT are needed.
Predictors of renal calcifications
In this study, patients with renal calcifications had higher levels of ionized calcium and PTH compared with patients without renal calcifications. This is in contrast to most other studies, showing no differences in biochemistry (3, 8, 9, 12, 15, 17, 18) . In two studies, higher levels of ionized calcium and PTH in patients with nephrolithiasis compared with patients without have been reported (11, 19) . Additionally, we found a higher 24-hour urinary calcium in patients with renal calcifications compared with those without. This is in accordance with some (3, 5, 11), but not all, prior studies (15, 18) . The pathogenesis behind stone formation remains unclear, although hypercalciuria seems to be importance. PTH increases plasma and urinary calcium through several mechanisms. PTH affects the kidneys by enhancing the tubular calcium reabsorption. However, in PHPT, the kidney's reabsorption capacity is exceeded due to a high filtered load of calcium (1) . Moreover, PTH stimulates the 25-OHD-1a-hydroxylase enzyme, thereby increasing the renal synthesis of 1,25(OH) 2 D, which increases the intestinal calcium reabsorption (32) . Furthermore, PTH stimulates bone resorption, resulting in an increased efflux of calcium from bone (33) . As shown in our study as well as by other investigators, the degree of hypercalciuria rises with increased plasma levels of calcium (34) . Our results support the hypothesis that hypercalciuria has a central role in stone formation in patients with PHPT. However, other urinary parameters may be of importance for renal calcifications. A nonsignificant tendency for lower urinary citrate and a higher urinary oxalate excretion in patients with nephrolithiasis compared with those without has been reported (11, 12) . This suggests that urinary calcium is not the only determinant for renal calcifications but that other urinary factors are of importance as well. Further studies are needed to evaluate urinary parameters in PHPT patients with renal calcifications and differences in urinary parameters between those with nephrolithiasis and nephrocalcinosis. Interestingly, a study by Scillitani et al. (35) reported a specific haplotype of calcium-sensitive receptor gene to be associated with stone formation in PHPT, supporting the multifactorial etiology behind renal calcifications.
Patients with nephrocalcinosis differed from patients with nephrolithiasis by higher levels of phosphate and a higher CaP-product. To our knowledge, our study is the first to report biochemical differences between PHPT patients with nephrolithiasis and nephrocalcinosis. These biochemical differences support the hypothesis of different pathogenic mechanisms behind nephrolithiasis and nephrocalcinosis. Further research is needed to elucidate urinary and nonurinary differences between these two groups. None of our PHPT patients had an elevated CaP-product (4.4 mmol 2 /L 2) . Further studies should aim to determine whether this limit of 4.4 mmol 2 /L 2 is appropriate in patients with PHPT.
Patients with nephrolithiasis had a higher body weight compared with patients with nephrocalcinosis. Previous studies have reported higher body weight in PHPT compared with the background population (36) . Higher BMI has also been associated with increased risk of nephrolithiasis, which may be due to increased excretion of oxalate, uric acid, phosphorus, and sodium (37) . Increased body weight in PHPT patients may contribute to the increased stone risk. However, further studies are needed to explore associations between body weight and risk of renal calcifications in PHPT.
Surprisingly, after mutual adjustment, the CaP-product was associated with lower risk of nephrolithiasis in multiple regression analyses. This is opposing the theory that higher levels of phosphate and the CaP-product are associated with increased risk of renal calcifications. However, PTH decreases tubular phosphate reabsorption, thereby lowering plasma phosphate. A possible explanation for this inverse association could be that relatively low plasma phosphate levels represent a more severe degree of the disease, whereas relatively high phosphate levels represent a milder degree of the disease.
Renal function in PHPT
Current international guidelines recommend parathyroidectomy if eGFR is below 60 mL/min (38) . However, only few studies have assessed associations between renal function and PHPT. In our study, 12% of patients had an eGFR below 60 mL/min, which is in accordance with the findings by Tassone et al. (39) , reporting an eGFR below 60 mL/min in 17% patients.
We did not observe any differences in renal functions between those with and without renal calcifications, and the prevalence of renal calcifications were equally frequent in the different CKD stages. This suggests that urinary obstruction is not a common feature of PHPT patients with renal stones. However, in multiple regression analyses, we observed that eGFR was inversely associated with Ca 2+ and PTH, suggesting that the severity of the disease is of importance to renal function (40) . This is in accordance with a population-based, matched cohort study in which renal failure in mild PHPT was increased by 13.8-fold (41) . In contrast to our findings, Walker et al. (42) did not observe any associations with Ca 2+ , PTH, or nephrolithiasis. However, the study showed an inverse association between renal function and diastolic blood pressure and age. Likewise, in a prospective study including 80 PHPT patients followed for up to 10 years without parathyroidectomy, creatinine levels did not change during the follow-up time (40) . Hypertension, obesity, and an impaired glucose intolerance have been associated with PHPT (36, 43, 44) and may also predispose to an impaired renal function in PHPT. Therefore, it remains unclear whether an impaired renal function is caused by PHPT by itself or by the traditional risk factors such as age and blood pressure. Further studies are needed to elucidate associations between renal function and PHPT.
Strengths and limitations
A strength of our study is that we validated the PHPT diagnosis by retrieving biochemical data and thereby excluding patients who did not meet the diagnostic criteria for PHPT. Furthermore, patients with hyperparathyroid hypercalcemia due to other disease such as FHH and CKDs were excluded. Our study population included mostly patients with mild hypercalcemia (61%), which reflects the most common presentation of PHPT today. Furthermore, the routine diagnostic workup with CT scan of the kidneys and urinary tract of all patients diagnosed with PHPT minimizes selection bias.
Limitations of the study are the lack of CT scan of the kidneys and urinary tract in one-fifth of the study population. Patients referred to a CT scan differed slightly but significantly from those not examined by a CT scan by being older, with a better renal function (higher eGFR) and less severe disease in terms of lower plasma levels of Ca 2+ and PTH. It may be speculated that physicians are more prone to abstain from referring older patients with milder disease to CT scans of kidneys and urinary tract. Moreover, lack of a control group in our study is a limitation, because we cannot compare the prevalence of renal calcifications or impaired renal function to the background population. Only PTH, ionized calcium, total calcium, and creatinine were all measured on the same blood samples, whereas other biochemical indices were measured during the clinical workup of patients. However, as severity of PHPT is known not to progress rapidly, we do not believe that this is of major importance to our findings. Furthermore, it was only possible to test for FHH type 1 during the study time. It is a limitation that CT scans were analyzed by a different radiologist and that the investigators were not blinded to the diagnosis of PHPT. Furthermore, we do not have any information about the use of vitamin D supplement, menopausal status, alcohol consumption, physical activity, smoking status, and blood pressure. Additionally, we do not have any information about symptoms associated with renal calcifications and therefore we do not know how many patients had silent or symptomatic disease.
Conclusion
We found an overall prevalence of renal calcifications of 23% in patients with PHPT. Higher levels of calcium and PTH were associated with renal calcifications, which supports the notion that severity of the disease is of importance to the development of nephrolithiasis and nephrocalcinosis. In PHPT, a high 24-hour renal excretion of calcium was associated with renal calcifications, which supports the hypothesis of hypercalciuria being of importance. eGFR below 60 mL/min was found in 12% of the patients. However, the prevalence of renal calcifications did not differ according to CKD stages. The relationship between renal function and PHPT needs to be elucidated further. Nephrocalcinosis was present in 12% of patients with PHPT. As nephrocalcinosis is only identified by imaging and the presence of nephrocalcinosis may lead to renal impairment, it seems to be of importance to perform imaging of the kidneys and urinary tract in all patients diagnosed with PHPT.
